Liraglutide enhances insulin sensitivity by activating amp-activated protein kinase in male wistar rats

Endocrinology (United States)

Volumn 155, Issue 9, 2014, Pages 3288-3301

  Yamazaki, Satoru ^a   Satoh, Hiroaki ^a   Watanabe, Tsuyoshi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; ADIPONECTIN; FATTY ACID SYNTHASE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LIRAGLUTIDE; PROTEIN KINASE B; STEROL REGULATORY ELEMENT BINDING PROTEIN; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID DIET; LIPOGENESIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; DRUG EFFECT; GENETICS; HUMAN; LIVER; METABOLISM; PHOSPHORYLATION; WISTAR RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ENZYME ACTIVATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR;

EID: 84907050065     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-2157     Document Type: Article

References (40)

1. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219-246.
2. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004;116(2):337-350.
3. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5(5):262-269.
4. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2008;93(10):3703-3716.
5. Wang Y, Perfetti R, Greig NH, et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest. 1997;99(12):2883-2889.
6. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144(12):5149-5158.
7. List JF, Habener JF. Glucagon-like peptide 1 agonists and the development and growth of pancreatic β-cells. Am J Physiol Endocrinol Metab. 2004;286(6):E875-E881.
8. Ahren B. GLP-1 and extra-islet effects. Horm Metab Res. 2004; 36(11-12):842-845.
9. Valverde I, Morales M, Clemente F, et al. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett. 1994;349(2):313-316.
10. Villanueva-Peñacarrillo ML, Alcántara AI, Clemente F, Delgado E, Valverde I. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia. 1994;37(11):1163-1166.
11. Galera C, Clemente F, Alcantara A, et al. Inositolphosphoglycans and diacyglycerol are possible mediators in the glycogenic effect of GLP-1(7-36)amide in BC3H-1 myocytes. Cell Biochem Funct. 1996;14(1):43-48.
12. Wheeler MB, Lu M, Dillon JS, Leng XH, Chen C, Boyd AE 3rd. Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology. 1993;133(1):57-62.
13. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
14. Elahi D, Egan JM, Shannon RP, et al. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity. 2008;16(7):1501-1509.
15. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004; 109(8):962-965.
16. Ryan GJ, Hardy Y. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes. J Clin Pharm Ther. 2011;36(3):260-274.
17. Satoh H, Audrey Nguyen MT, Kudoh A, Watanabe T. Yacon diet (Smallanthus sonchifolius, Asteraceae) improves hepatic insulin resistance via reducing Trb3 expression in Zucker fa/fa rats. Nutr Diabetes. 2013;3:e70.
18. Racioppi L, Noeldner PK, Lin F, Arvai S, Means AR. Calcium/calmodulin-dependent protein kinase kinase 2 regulates macro-phage-mediated inflammatory responses. J Biol Chem. 2012; 287(14):11579-11591.
19. Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I, Olefsky JM. Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest. 2004;114(2):224-231.
20. Satoh H, Nguyen MT, Trujillo M, et al. Adenovirus-mediated adi-ponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes. 2005;54(5):1304-1313.
21. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci. 1959;82:420-430.
22. Saltiel AR, Kahn CR. Insulin signalling and the regulation ofglucose and lipid metabolism. Nature. 2001;414(6865):799-806.
23. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007;100(3):328-341.
24. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endo-thelial cells. J Biol Chem. 2003;278(45):45021-45026.
25. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S. Antidiabeto-genic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992; 326(20):1316-1322.
26. López-Delgado MI, Morales M, Villanueva-Peñacarrillo ML, Mal-aisse WJ, Valverde I. Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats. Endocrinology. 1998;139(6):2811-2817.
27. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J. Glu-cagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology. 1994; 135(5):2070-2075.
28. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest. 1994;93(5):2263-2266.
29. Shalev A, Ninnis R, Keller U. Effects of glucagon-like peptide1(7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Horm Res. 1998;49(5): 221-225.
30. Orskov L, Holst JJ, Møller J, et al. GLP-1 does not not acutely affect insulin sensitivity in healthy man. Diabetologia. 1996;39(10):1227-1232.
31. Ryan AS, Egan JM, Habener JF, Elahi D. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab. 1998;83(7):2399-2404.
32. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes. 2001;50(11):2530-2539.
33. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacar-rillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol. 1997;273(4 pt 1):G920-G927.
34. Jia X, Brown JC, Kwok YN, Pederson RA, McIntosh CH. Gastric inhibitory polypeptide and glucagon-like peptide-1(7-36) amide exert similar effects on somatostatin secretion but opposite effects on gastrin secretion from the rat stomach. Can J Physiol Pharmacol. 1994;72(10):1215-1219.
35. Woods A, Cheung PC, Smith FC, et al. Characterization of AMP-activated protein kinase β and γ subunits. Assembly of the hetero-trimeric complex in vitro. J Biol Chem. 1996;271(17):10282-10290.
36. Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ. Evidence for 5' AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes. 1998;47(8): 1369-1373.
37. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3(3):153-165.
38. He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137(4):635-646.
39. Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51(5):1584-1592.
40. Panjwani N, Mulvihill EE, Longuet C, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE (-/-) mice. Endocrinology. 2013;154(1):127-139.